Sanofi and SK Chemicals Sign Licensing Agreement for Flu Vaccine Technology
2018年2月13日 - 2:36AM
Dow Jones News
By Sonia Amaral Rohter
Sanofi SA's (SAN.FR) vaccines division, Sanofi Pasteur, and SK
Chemicals Co. Ltd. (285130.SE) have signed a licensing agreement
for flu vaccine technology, SK Chemicals said on Monday.
Under the terms of the agreement, Sanofi Pasteur will pay SK
Chemicals up to $155 million, including milestone payments, to
license SK Chemicals's cell-culture based manufacturing technology
for influenza vaccines.
Sanofi Pasteur is licensing the technology for use in its
efforts to develop a broadly protective flu vaccine, SK Chemicals
said. Broadly protective influenza vaccines are designed to protect
against many different strains of the virus.
"We're pleased to license this innovative technology today, as
it brings us a step forward in the development of a future
broadly-protective influenza vaccine, a key priority for Sanofi
Pasteur," said Sanofi Pasteur Chief Executive David Loew.
Sanofi Pasteur is the world's largest producer of influenza
vaccine, according to its webpage.
Write to Sonia Amaral Rohter at
sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
February 12, 2018 12:21 ET (17:21 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
過去 株価チャート
から 3 2024 まで 4 2024
Sanofi (EU:SAN)
過去 株価チャート
から 4 2023 まで 4 2024